Prostate cancer (PC) remains the third most common cause of cancer death in men in the developed world ([@bib13]). Docetaxel chemotherapy offers both symptomatic and survival benefits in men with metastatic castrate-resistant PC (mCRPC), however, only 48--50% of men treated with Docetaxel benefit from treatment ([@bib21]; [@bib29]). A high proportion of patients experience significant toxicity; 42% nausea, vomiting or both, 30% sensory neuropathy and 26% more than or equal to one serious adverse event ([@bib21]; [@bib29]). The newer second-line cytotoxic, Cabazitaxel, similarly improves survival, but remains toxic and benefits \<50% of patients ([@bib8]). Clearly, patients would benefit from knowing early in the treatment schedule, who will benefit from chemotherapy to avoid the morbidity in an elderly population.

Glutathione S-transferases (GSTs) are a family of enzymes that catalyse intracellular detoxification of a variety of electrophiles, including a number of xenobiotics and carcinogens ([@bib25]). Human GSTs are classified into distinct families; five of the gene families encode cytosolic GSTs, (alpha, mu, pi, sigma and theta), whereas single genes encode membrane-bound forms of the enzyme ([@bib12]). Among the isozymes, the pi class enzyme *Glutathione S-transferase 1* (*GSTP1*) is the most widely distributed ([@bib26]) and many groups including our own have shown that *GSTP1* expression is inactivated in \>90% of all PCs([@bib17]; [@bib19]) in association with aberrant DNA methylation of its CpG island associated promoter and first exon ([@bib19]). PC can be diagnosed by the detection of methylated *GSTP1* DNA *(mGSTP1)* in urine and semen samples ([@bib3]). Detectable *mGSTP1* in the pre-operative serum of men with localised PC is associated with biochemical relapse ([@bib2]), whereas detectable serum *mGSTP1* is present in 28--32% of men with metastatic PC ([@bib2]; [@bib23]). However, there are no longitudinal data assessing the changes in levels during the progression and treatment of individual patients ([@bib2]).

Although the level of circulating tumour cells (CTCs) is prognostic and associated with chemoresponse in CRPC, quantitation is cumbersome and prone to technical challenges including cell lysis ([@bib6]; [@bib9]; [@bib27]). Detection of methylated *GSTP1* in free DNA from plasma provides a stable marker to identify tumour DNA in the circulation and offers the potential to assess response to therapy. This study aimed to determine whether quantitative measurement of plasma *mGSTP1* free DNA is associated with response to chemotherapy and overall survival (OS) in men with mCRPC.

Materials and methods
=====================

This study was reported in accordance with REMARK guidelines ([@bib18]).

Patient population and plasma samples
-------------------------------------

The phase I exploratory cohort ([Figure 1A](#fig1){ref-type="fig"}) consisted of 75 men with mCRPC, who had blood samples obtained at the time of presentation to Medical Oncology (Royal Prince Alfred Hospital, Concord Hospital and Royal North Shore Hospital) between June 2006 and July 2009. Patients were seen every 6--12 weeks and had blood samples obtained each visit. Men who subsequently had chemotherapy (Docetaxel 75 mg m^−2^ 3-weekly or Mitoxantrone 12 mg m^−2^ 3-weekly) had blood samples drawn prior to each cycle of treatment. The phase II independent validation cohort ([Figure 1B](#fig1){ref-type="fig"}) consisted of 51 men who were receiving chemotherapy (Docetaxel 75 mg m^−2^ 3-weekly, Cabazitaxel 25 mg m^−2^ 3-weekly or Mitoxantrone 12 mg m^−2^ 3-weekly) for mCRPC, who had blood samples obtained prior to commencing chemotherapy and just prior to their second cycle of treatment and were enrolled between April 2009 and September 2012 from hospitals in the PRIMe (Pharmacogenomic Research for Individualized Medicine) network: Sydney Cancer Centre (Royal Prince Alfred Hospital and Concord Hospital), the SAN Clinic, Westmead Hospital and the Mater Misericorde Newcastle Hospital. Blood samples were collected according to a standardised operating procedure using 0.109 [M]{.smallcaps} buffered sodium citrate for the CTC preparation, BD Vacutainer tubes containing K~2~EDTA for plasma samples and BD Vacutainer tubes containing clot activator and gel separation for serum samples. For the Phase I exploratory cohort, 7.5 ml of whole blood was also obtained for each assay and free DNA was collected using the QIAamp MinElute Virus Spin Kit, according to the manufacturer\'s directions. For the Phase II validation cohort, 1 ml of plasma was assayed for each time point. Samples were centrifuged and couriered at 4 °C to a central laboratory (Garvan Institute of Medical Research). Within 12 h of collection, CTCs were analysed and plasma was stored at −80 °C.

PSA partial response (PR) was defined as a 50% or greater decrease in serum PSA compared with the last value assessed prior to initiation of chemotherapy ([@bib21]; [@bib29]). PSA progressive disease (PD) was defined as an increase in PSA value by \>25% over the baseline, and stable disease (SD) was defined as a value \>0.5 but \<1.25 times the baseline value ([@bib21]; [@bib29]). Overall survival was calculated from the date of the baseline biomarker blood draw to the date of death or last follow-up. Eastern Cooperative Oncology Group performance status (ECOG PS) assessment, serum haemoglobin (Hb) and serum alkaline phosphatase (ALP) data were collected prospectively, but not available for all participants. Radiological assessments were according to standard practice, were variable and unsuitable for determining objective tumour response.

All patients provided written informed consent, and the study was approved by human research ethics review committees at all participating institutions, and was registered on the Australian New Zealand Clinical Trials Registry.

### Methylation-specific head-loop PCR (MS-HL PCR) GSTP1 assay

Bisulphite treatment was carried out on all plasma-free DNA samples for 4 h (Zymo EZ-96 DNA Methylation-Gold Kit \#D5008). The *GSTP1* methylation-sensitive headloop (MS-HL) PCR assay was performed as previously described to measure the absolute amount of methylated *GSTP1* DNA in the DNA samples ([@bib22]). Forward primer: 5′ACACAACCCACATCCCCAAAATGTTGGGAGTTTTGAGTTTTATTTT; Reverse primer: 5′ AAAACCICIAAACCTTCICTAAAATTTC; Probe: 5′ VIC-TCG CCG CCG CAA T-MGBNFQ. The control *GSTP1* PCR reaction was used to measure the amount of total DNA in the sample. Forward primer: 5′GGG ATT ATT TTT ATA AGG TTY GGA GGT; Reverse primer: 5′ AAA ACC CRA ACC TAA TAC TAC RAA TTA A; Probe 5′ FAM-CCC CAT ACT AAA AAC TCT AAA CCC CAT CCC. PCR reaction conditions: 95 °C for 120 s, 50 cycles at 95 °C for 15 s, 60 °C for 60 s. Real-time PCR was carried out in triplicate using an ABI PRISM ABI7900 Sequence Detection System. The average triplicate Ct values from the *GSTP1* MS-HL PCR assay were used to estimate the quantity of methylated DNA in the plasma and serum DNA samples using the standard curve ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}), generated using known (1 ng, 5 ng, 10 ng, 50 ng, 100 ng, 500 ng) concentrations of SssI fully methylated DNA into unmethylated DNA, as described previously([@bib22]). Detectable *mGSTP1* was defined as \>1 ng per plasma sample. These assays were performed blinded to the clinical outcomes of the patients.

### Statistical analysis

Plasma and serum levels of *mGSTP1* were not normally distributed, so we used McNemar\'s test and linear regression after log-transformation to determine relationships between the different DNA assays. Reported correlations are based on regression of the log-transformed values. ANOVA was used to assess the relationship between plasma *mGSTP1* levels, the sites of metastases and Gleason score. The relationship between plasma *mGSTP1* levels (detectable *vs* undetectable) and PSA response to chemotherapy (PR and SD *vs* PD) was assessed with the *χ*^2^-test. Kaplan--Meier curves and the log-rank test were used to assess the association between increased plasma *mGSTP1* levels and OS. Cox proportional hazards regression was used for multivariable analyses assessing the relationship between change in plasma *mGSTP1* levels (detectable *vs* undetectable) and previously identified clinicopathologic variables. All reported *P*-values are two-sided. A *P*-value of 0.05 was used as the criterion for statistical significance without any adjustment for multiple testing. All statistical analyses were performed using Statview 4.5 software (Abacus Systems, Berkeley, CA, USA).

Results
=======

Efficacy of *mGSTP1* assays
---------------------------

In the phase I exploratory cohort, we initially used immunomagnetic bead separation of CTCs to assess levels of *mGSTP1* in blood from men with CRPC. Isolation of CTCs is expensive and labour-intensive, so we assessed whether free DNA isolated from plasma would be a more sensitive technique for assessment of *mGSTP1* levels. For the sequential samples from the first 34 patients (172 paired samples), DNA was isolated from both CTC and plasma samples obtained from ficoll preparations ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). In the paired DNA samples, *mGSTP1* was detected approximately twice as frequently in plasma-free DNA 74/172 (43%) than in DNA from CTCs 35/172 (20%) (McNemar\'s test, *P*\<0.0001), with a moderate correlation between the log-transformed values measured by the two techniques (*R*^2^=0.42, [Figure 2A](#fig2){ref-type="fig"}). Owing to the higher sensitivity for *mGSTP1* detection, free plasma DNA was used for the remainder of the study.

Based on the clinical need that a practical assay is required across a wide range of clinical settings, paired plasma samples were collected to assess further refinements in the technique ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). We compared free plasma DNA from Ficoll preparation and DNA from plasma spin from 28 patients (98 paired samples) and found that they correlated well (*R*^2^=0.73, [Figure 2B](#fig2){ref-type="fig"}). We also compared serum and plasma samples from 32 patients (178 paired samples) using spin protocol and found significant correlation (*R*^2^=0.81, [Figure 2C](#fig2){ref-type="fig"}). These data indicated that the *mGSTP1* assay could be reliably performed on DNA obtained using a simple spin protocol in either serum or plasma samples. All the results described subsequently used quantitative *mGSTP1* levels from free DNA from plasma spin.

*mGSTP1* levels as prognostic marker in Phase I exploratory cohort
------------------------------------------------------------------

The Phase I exploratory patient cohort consisted of 75 men with CRPC, of whom 89% had chemotherapy during the course of their disease. The baseline characteristics are summarised in [Table 1](#tbl1){ref-type="table"}. The median follow-up was 16 months (range 1--44 months) with 51 deaths (68%).

*mGSTP1* was detectable in free plasma DNA in two thirds (50/75) of men at presentation to Medical Oncology with CRPC. The undetectable *mGSTP1* cohort (25/75) represented 88% (7/8) of those with no metastases, 29% (12/42) with bone only metastases and 29% (6/21) with both bone and visceral metastases. Men with higher Gleason score 9/10 cancers were more likely to have detectable mGSTP1 compared with men with Gleason score 7/8 cancers (82% *vs* 65%). There was a non-significant trend towards increased *mGSTP1* levels in men with bone metastases ([Supplementary Figure 3A](#sup1){ref-type="supplementary-material"}) and the levels of *mGSTP1* were higher in men with Gleason scores of 9 or 10 *vs* 8 or lower (*P*=0.07; [Supplementary Figure 3B](#sup1){ref-type="supplementary-material"}).

Survival analysis demonstrated that detection of plasma *mGSTP1* at presentation to Medical Oncology with CRPC was associated with a shorter OS (HR 4.2, 95% CI 2.1--8.2; *P*\<0.0001; [Figure 3A](#fig3){ref-type="fig"}). The 2-year survival for men with no detectable plasma *mGSTP1* was 71% compared with 23% for men with detectable plasma *mGSTP1* levels ([Figure 3A](#fig3){ref-type="fig"}). Receiver operating characteristic curve analysis confirmed that detectable *mGSTP1* at baseline was associated with death within 12 months (AUC 0.78, 95% CI 0.67--0.89; *P*\<0.001; [Figure 3B](#fig3){ref-type="fig"}). Baseline levels of plasma *mGSTP1*, serum PSA, serum Hb, Gleason score and serum ALP were prognostic for OS ([Table 2](#tbl2){ref-type="table"}) on univariable analysis. Performance status was not significant though there were missing data from 40% of patients. Serum LDH was not recorded. On multivariable analysis, detectable *mGSTP1* at baseline (HR 3.3, 95% CI 1.4--7.9; *P*=0.006) and higher levels of baseline serum PSA (HR 1.001, 95% CI 1.0--1.001; *P*=0.002) were significantly associated with poorer survival ([Table 2](#tbl2){ref-type="table"}).

*mGSTP1* levels as a therapeutic efficacy marker in Phase I exploratory cohort
------------------------------------------------------------------------------

Although 67 patients in the cohort were treated with chemotherapy, only 35 patients had sequential plasma samples drawn pre/post the first cycle of chemotherapy. Docetaxel treatment was used in 30 patients and the remainder received Mitoxantrone ([Figure 1A](#fig1){ref-type="fig"}). The patients\' characteristics are summarised in [Table 3](#tbl3){ref-type="table"}. The median follow-up was 15 months (range 2--38 months), with 22 deaths (63%). Of the 35 patients, 30 had detectable plasma *mGSTP1* DNA prior to starting chemotherapy. Detectable plasma *mGSTP1* at baseline was associated with shorter OS (HR 6.8, 95% CI 1.5--30.4; *P*=0.01), but was not associated with subsequent PSA response to therapy (*P*=0.3). An increase in plasma *mGSTP1* DNA levels after the first cycle of chemotherapy was associated with subsequent PSA progression (*P*=0.008, [Figure 3C](#fig3){ref-type="fig"}).

Phase II independent validation cohort
--------------------------------------

The Phase II validation cohort consisted of 51 men with mCRPC, all of whom received chemotherapy and had paired blood samples available (pre/post one cycle of chemotherapy) ([Figure 1B](#fig1){ref-type="fig"}). The baseline clinical characteristics are detailed in [Table 3](#tbl3){ref-type="table"}. There were 28 deaths (55%) after a median follow-up of 12 months (range 2--33 months). Prior to chemotherapy, 59% of patients (30/51) had detectable plasma *mGSTP1* DNA, and it was detectable after one cycle of chemotherapy in 37% of patients (19/51). Most patients (96%) were treated with docetaxel ([Table 3](#tbl3){ref-type="table"}). The PSA PR rate was 33/51 (65%), with SD in 13 (25%), and PD in 5 (10%) ([Table 3](#tbl3){ref-type="table"}).

The phase II validation cohort confirmed the prognostic significance of plasma *mGSTP1* DNA levels. Detectable plasma *mGSTP1* prior to chemotherapy was associated with shorter OS (HR 2.4, 95% CI 1.0--5.6; *P*=0.039; [Figure 4B](#fig4){ref-type="fig"}, [Table 4](#tbl4){ref-type="table"}) as was a detectable *mGSTP1* after one cycle of chemotherapy (HR 3.7, 95% CI 1.6--8.2; *P*=0.001; [Supplementary Figure 4](#sup1){ref-type="supplementary-material"}). In concordance with the TAX327 study ([@bib1]), we found that a ⩾30% decline in serum PSA at 3 months was associated with longer OS (*P*=0.002, [Figure 4C](#fig4){ref-type="fig"}). Receiver operating characteristic curve analysis demonstrated that detectable plasma *mGSTP1* at baseline and after one cycle of chemotherapy were better predictors of death within 12 months than change in PSA after 3 months ([Figure 4D](#fig4){ref-type="fig"}).

Univariable analysis revealed that baseline detectable plasma *mGSTP1* (*P*=0.049), Gleason score (*P*=0.04) and high baseline ALP (*P*=0.002) were significantly associated with a poorer OS ([Table 4](#tbl4){ref-type="table"}). Detectable *mGSTP1* at baseline was an independent predictor of OS in multivariable analyses adjusting for baseline PSA, Gleason Score and Hb concentration (*P*\<0.05; [Table 4](#tbl4){ref-type="table"}). Serum LDH and ECOG performance status were not available.

High *mGSTP1* levels after one cycle of chemotherapy were associated with PSA progression on ROC curve analysis (*P*=0.006; [Figure 4A](#fig4){ref-type="fig"}). Baseline levels of *mGSTP1* were not significantly associated with PSA response (*P*\>0.05).

Discussion
==========

This study identifies plasma *mGSTP1*-free DNA as a potential epigenetic marker of prognosis and therapeutic response in CRPC. Detectable plasma levels of *mGSTP1* at presentation with CRPC were associated with poorer survival irrespective of cytotoxic treatment. In addition, detectable plasma *mGSTP1* DNA after cycle 1 of chemotherapy was associated with progressive disease and a poorer OS irrespective of response to chemotherapy. Furthermore, the assay for *mGSTP1* based on circulating DNA was more sensitive than that based on DNA extraction from CTC.

Assessment of treatment efficacy in the setting of CRPC remains a challenge. The TAX327 and SWOG9916 trials used PSA response, objective tumour response, improvements in pain and quality of life as secondary measures of treatment effect ([@bib21]; [@bib29]). However, 20% of men, who eventually had a PSA response to chemotherapy, had an initial rise in their serum PSA and the median time to PSA response was 44 days (range 26--68 days), so most patients received two or more cycles of treatment before their response status could be ascertained ([@bib29]). Trials of Sipuleucel-T have demonstrated improvements in OS, without demonstrating effects on other outcomes measures ([@bib16]). The identification of earlier and more reliable markers of disease response are needed.

The assessment of CTC numbers to determine prognosis and monitor treatment efficacy is the most developed biomarker in CRPC. The Cellsearch system (Johnson & Johnson, New Brunswick, NJ, USA) is the only CTC technology that has been FDA approved for the monitoring of disease status in PC ([@bib5]). Baseline numbers of CTC before treatment were independently prognostic for survival analysed as a continuous variable ([@bib7]; [@bib28]) or using a cutoff (⩾5 CTC per 7.5 ml blood *vs* 4 CTC) ([@bib9]). Furthermore, changes in the number of CTC after treatment were more strongly associated with survival than were changes in PSA at 4, 8 and 12 weeks post treatment ([@bib9]; [@bib28]). Our assay for plasma *mGSTP1* levels at baseline, and after 1 cycle of chemotherapy, were also strongly predictive of OS. However, our study is limited by its lack of direct comparison with CTC enumeration (CellSearch platform) as this technology was not available in Australia at the time. Despite this, the plasma *mGSTP1* assay has several advantages: (1) the blood for a *mGSTP1* assay can be collected in a standard EDTA tube rather than a specialised CTC tube (CellSave Preservative Tube, Johnson & Johnson), (2) the sample for a *mGSTP1* assay can be spun and frozen for later assaying, as DNA methylation is a stable marker, as opposed to the CTC assay that must be run within 96 h of blood collection and (3) the *mGSTP1* assay uses standard RT-PCR assay equipment available in most diagnostic laboratories, rather than requiring a specialised machine.

The identification of hypermethylated *GSTP1* DNA in plasma in cancer patients is well documented ([@bib30]; [@bib14]). Hypermethylation of *GSTP1* can be detected in samples of prostate, urine and blood. *GSTP1* hypermethylation has high specificity (86.8--100%), but low sensitivity for PC detection in both urine (18.8--38.9%) and serum/plasma (13.0--72.5%)([@bib10]; [@bib4]; [@bib15]; [@bib11]; [@bib24]). In the advanced PC setting, elevated plasma *mGSTP1* levels have been correlated with higher Gleason score at diagnosis ([@bib23]). A recent study of the relationship between CTC levels and several methylated plasma markers, including *GSTP1,* in 76 men with CRPC demonstrated a significant correlation between ⩾5 CTCs and the detection of *mGSTP1* (*P*\<0.001) ([@bib20]). Furthermore, men with detectable CTCs and elevated methylated markers in plasma had a poorer prognosis than those with either marker alone ([@bib20]). Our study is the first to assess changes in plasma *mGSTP1* after chemotherapy. The detection of *mGSTP1* can now be done routinely in the clinic with recent commercialisation of PCR-based assays.

Conclusions
===========

We have identified plasma *mGSTP1* levels as a potential prognostic marker in men with CRPC, raised the hypothesis that plasma *mGSTP1*-free DNA levels could be a potential surrogate measure of therapeutic efficacy for cytotoxic chemotherapy and corroborated these findings in an independent Phase II cohort. Assessment of methylated DNA can be performed in a routine pathology laboratory and, unlike CTC, is a stable marker that can still be measured after long-term storage. These data strongly suggest that plasma *mGSTP1* levels warrant further investigation, comparison with CTC enumeration, and assessment within prospective clinical trials to determine its clinical utility as a biomarker for response to chemotherapy in CRPC.
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![**CONSORT diagram of recruitment of Phase I exploratory and Phase II validation cohorts.**](bjc2014463f1){#fig1}

![**The relationship between different techniques for extracting DNA assessment of *mGSTP1* levels in the Phase I exploratory cohort.** (**A**) A regression analysis of the relationship between *mGSTP1* results from DNA extracted from CTC *vs* free plasma DNA from a ficoll preparation (*n*=172 paired blood samples). (**B**) A regression analysis of the relationship between *mGSTP1* results from free plasma DNA from a ficoll preparation *vs* free plasma DNA from a spin preparation (*n*=98 paired blood samples). (**C**) A regression analysis of the relationship between *mGSTP1* results from free plasma DNA from a spin preparation *vs* free serum DNA from a spin preparation (*n*=178 paired blood samples).](bjc2014463f2){#fig2}

![**The relationship between plasma *mGSTP1,* overall survival and response to chemotherapy in men with CRPC in the Phase I exploratory cohort (*n*=75).** (**A**) Kaplan--Meier analysis of the relationship between plasma *mGSTP1* levels (detectable *vs* undetectable) at presentation to Medical Oncology with CRPC and overall survival demonstrating that detectable plasma *mGSTP1* is associated with a poorer prognosis. (**B**) Receiver operating characteristic curve assessing the association between baseline *mGSTP1* and death within 12 months. (**C**) Plasma *mGSTP1* levels in men with CRPC treated with chemotherapy in the Phase I exploratory cohort (*n*=35). The relationship between the change in *mGSTP1* levels after chemotherapy and the response to chemotherapy is shown in a Waterfall plot assessing the differences between responders (PR) and non-responders (PD/SD). Fold changes \>500 were capped at 500 to assist with the presentation of the data. The association between the change in *mGSTP1* levels and response to chemotherapy was assessed using a *χ*^2^ analysis.](bjc2014463f3){#fig3}

![**The relationship between plasma *mGSTP1* levels, overall survival and response to chemotherapy in men with CRPC in the Phase II validation cohort (*n*=51).** (**A**) Receiver operating characteristic curve assessing the association between plasma *mGSTP1* after one cycle of chemotherapy (detectable *vs* undetectable) and chemoresistance (PD *vs* SD+PR). (**B**) Kaplan--Meier analysis of the relationship between plasma *mGSTP1* levels prior to chemotherapy (detectable *vs* undetectable) and overall survival demonstrating that detectable baseline plasma *mGSTP1* is associated with a poorer prognosis. (**C**) Kaplan--Meier analysis of the relationship between a ⩾30% decline in PSA at 3 months after commencing chemotherapy and overall survival. (**D**) Receiver operating characteristic curve assessing the association between plasma *mGSTP1* (detectable *vs* undetectable) at baseline, plasma *mGSTP1* after one cycle of chemotherapy, decline in PSA at 3 months and death within 12 months.](bjc2014463f4){#fig4}

###### Clinicopathological characteristics of the Phase I exploratory cohort of men presenting to Medical Oncology with CRPC (*n*=75)

  **Characteristics**                                   **Number (% or range)**
  ----------------------------------------------------- ---------------------------------
  Age at enrolment (median)                             73 (range 52--91)
  **Course of treatment (*n*=88)**                      
  No treatment                                          8 (11)
  Docetaxel-based chemotherapy                          63 (84)
  Mitoxantrone                                          17 (23)
  2+ lines of chemotherapy                              13 (17)
  Median baseline PSA (*n*=74)                          110 ng ml^−1^ (range 5.9--5309)
  Median baseline haemoglobin (*n*=73)                  127 g l^−1^ (range 14--163)
  Median baseline serum alkaline phosphatase (*n*=71)   144 IU l^−1^ (range 19--1692)
  **Baseline ECOG (*n*=45)**                            
  0                                                     20 (44%)
  1                                                     21 (47%)
  2                                                     4 (9%)
  **Metastatic site**                                   
  None                                                  8 (11%)
  Bone only                                             42 (56%)
  Visceral/soft tissue                                  4 (5%)
  Bone and visceral                                     21 (28%)
  **Gleason score at diagnosis (*n*=61)**               
  4--6                                                  13 (21%)
  7                                                     15 (25%)
  8                                                     11 (18%)
  9                                                     16 (26%)
  10                                                    6 (10%)

###### Cox proportional hazards model of baseline factors, which are associated with overall survival in men presenting with CRPC in the Phase I exploratory cohort (*n*=75)

                                                                    **Univariable**      **Multivariable**                        
  ----------------------------------------------------------------- -------------------- ------------------- -------------------- -------
  Plasma *mGSTP1* present *vs* absent                               4.2 (2.1--8.2)       \<0.0001            3.3 (1.4--7.9)       0.006
  Serum PSA, ng ml^−1^[a](#t2-fn1){ref-type="fn"}                   1.0 (1.0--1.001)     0.004               1.001 (1.0--1.001)   0.002
  Haemoglobin, g l^−1^[a](#t2-fn1){ref-type="fn"}                   0.99 (0.98--0.999)   0.04                0.99 (0.98--1.001)   0.07
  Gleason score[a](#t2-fn1){ref-type="fn"}                          1.3 (1.01--1.6)      0.04                1.2 (0.97--1.6)      0.09
  Serum alkaline phosphatase, IU l^−1^[a](#t2-fn1){ref-type="fn"}   1.001 (1.0--1.002)   0.006               1.001 (1.0--1.002)   0.1
  ECOG PS 2 *vs* 0,1                                                1.6 (0.8--3.2)       0.2                 --                   --
  Docetaxel chemotherapy                                            0.77 (0.3--1.7)      0.5                 --                   --
  **Metastatic site**                                                                                                             
  Bone only                                                         2.1 (0.7--6.6)       0.2                 --                   --
  Visceral/soft tissue                                              0.3 (0.1--1.4)       0.12                                      
  Bone and visceral                                                 1.3 (0.7--2.4)       0.5                                       

Continuous variable.

###### Baseline clinical characteristics of patient cohorts receiving chemotherapy with paired blood samples before and after cycle 1 of chemotherapy

                                     **Median (range) or *N* (%)**  
  --------------------------------- ------------------------------- -------------------
  Number of patients                              35                        51
  Age (years)                              70 (range 59--83)         69 (range 48--86)
  Gleason score at diagnosis                    *n*=25                    *n*=42
   4--6                                         2 (8%)                    3 (7%)
   7                                           10 (40%)                   9 (21%)
   8                                            3 (12%)                  10 (24%)
   9                                           10 (40%)                  19 (46%)
   10                                              0                      1 (2%)
  PSA (ng ml^−1^)                            359 (6--4984)             134 (3--3822)
  Haemoglobin (g l^−1^)                      127 (95--167)             118 (67--158)
  Alkaline phosphatase (IU l^−1^)           142 (50--2962)            198 (15--1074)
  Number of chemotherapy lines                    40                        51
   Docetaxel                                   31 (78%)                  45 (88%)
   Mitoxantrone                                 9 (22%)                   2 (4%)
   Cabazitaxel                                     0                      4 (8%)
   2+ chemotherapy lines                        5 (13%)                      0
  Metastatic site                               *n*=35                    *n*=46
   None                                         2 (6%)                    1 (2%)
   Bone                                        16 (40%)                  26 (56%)
   Visceral/lymph node                          4 (11%)                   4 (9%)
   Bone and visceral                           13 (37%)                  15 (33%)
  Median follow-up (months)                   15 (2--38)                12 (2--33)

###### Cox proportional hazards model of baseline factors, which are associated with overall survival in men with CRPC receiving chemotherapy in the Phase II validation cohort (*n*=51)

                                                                **Univariable**      **Multivariable**   **Multivariable**                             
  ------------------------------------------------------------- -------------------- ------------------- ------------------- ------ ------------------ ------
  Plasma *mGSTP1* present *vs* absent                           2.4 (1.0--5.6)       0.049               2.9 (1.1--7.7)      0.03   2.7 (1.1--6.9)     0.04
  Serum PSA, ng ml^−1^[a](#t4-fn1){ref-type="fn"}               1.0 (0.99--1.0)      0.9                 1.0 (0.99--1.0)     0.3    1.0 (1.0--1.001)   0.03
  Haemoglobin, g l^−1^[a](#t4-fn1){ref-type="fn"}               0.97 (0.9--1.002)    0.06                0.98 (0.95--1.0)    0.2    --                 --
  Gleason score[a](#t4-fn1){ref-type="fn"}                      1.6 (1.0--2.6)       0.04                --                  --     1.9 (1.1--3.1)     0.02
  Serum alkaline phosphatase, IU/L[a](#t4-fn1){ref-type="fn"}   1.002 (1.0--1.003)   0.02                --                  --     --                 --
  ECOG PS 2 *vs* 0,1                                            NA                   NA                  --                  --     --                 --
  Docetaxel chemotherapy                                        0.59 (0.17--2.10)    0.4                 --                  --     --                 --
  **Metastatic site**                                                                                                                                  
  Bone only                                                     1                                                                                       
  Visceral/soft tissue                                          1.8 (0.4--8.0)       0.5                 --                  --     --                 --
  Bone and visceral                                             1.4 (0.6--3.2)       0.4                                                                

Continuous variable.
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